CA-CROWN-BIOSCIENCE
7.10.2021 14:32:07 CEST | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company and leader in translational services that help biopharmaceutical companies accelerate new drug development programs, today announced the launch of its ‘3D Ex Vivo Patient Tissue Platform’. Using freshly collected patient tumor material, this new service can accurately measure oncology and immuno-oncology drug-induced tumor killing and endogenous immune cell proliferation in a high throughput format. Researchers are presenting data on the new platform at this year’s AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , which is happening virtually on October 7-10, 2021.
The proprietary technology, developed at Crown Bioscience’s recently acquired site in Leiden, The Netherlands (formerly known as OcellO B.V.), aims to improve clinical success rates by using the most patient-relevant tumor samples to better predict tumor response to potential drug candidates.
“Our goal is to leverage our core technologies to build a translational model system that adequately captures the tumor architecture and microenvironment, and improves the predictability of patient responses to treatment protocols for existing and potential therapeutic candidates,” said Leo Price, PhD, Senior Vice President, In Vitro . “We believe this approach provides greater translational relevance in drug development by using immuno-competent primary human tumor tissue to help analyze drug candidate responses before the program enters clinical trial. This approach is an optimal fit with our mission to help deliver the right drug to the right patient at the right time.”
The ‘3D Ex Vivo Patient Tissue Platform’ utilizes patient tumor tissue isolated from biopsies, surgical resections, ascites, or pleural effusion samples that are processed within 24 hours to preserve the tumor microenvironment. The automated high throughput platform uses high content 3D imaging and image analysis to quantify distinct responses of individual cell populations in fresh patient tissues. These analyses can assess responses to different doses of therapeutic candidates at various timepoints and can determine the effects of the drug or combination of drugs on tumor killing and immune cell proliferation.
“We believe this new service can help fill a critical gap in today’s research landscape with early translational patient-relevant ex vivo models that can assess efficacy and determine mechanisms of action,” commented Armin Spura, PhD, Chief Executive Officer of Crown Bioscience . “This new service offering is designed to help mitigate the high failure rates of clinical programs in oncology, and was one of the objectives coming out of our recent OcellO acquisition. We are delighted to provide immediate value to our customers from this investment and look forward to the future value that this acquisition will bring.”
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Researchers from CrownBio are conducting a poster presentation titled, “Novel Near Vivo Drug Response Platform for Oncology using 3D Ex Vivo Patient-Derived Microtumors” at the annual conference. The poster summarizes:
- This 3D high content assay on ex vivo patient tumor material preserves native tumor microenvironement and architecture
- Ex vivo testing using ultra fresh patient tumor samples maintains intact endogenous immune cell populations
- Ongoing clinical trial collaborations with tissue providers for ovarian cancer, bladder cancer, NSCLC, and other tumor samples
For more information on Crown Bioscience’s 3D Ex Vivo Patient Tissue Platform, visit Crown Bioscienes's webpage on the new service.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development services company providing translational platforms to advance oncology, immuno-oncology, and immune mediated inflammatory disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005565/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Impartner Recognized as a Leader in G2 Summer 2026 Enterprise Grid® for Partner Relationship Management4.6.2026 15:00:00 CEST | Press release
Named a G2 Leader in both Partner Relationship Management and Through-Channel Marketing, reflecting strong customer satisfaction and enterprise momentum. Impartner, the world’s leading partner revenue orchestration platform, today announced it has been named a Leader in the G2 Summer 2026 Enterprise Grid® Report for Partner Relationship Management (PRM). The recognition underscores Impartner’s strong customer validation and continued momentum among enterprise organizations managing large-scale partner ecosystems and indirect sales channels. In the Summer 2026 report, Impartner earned Leader status based on strong customer satisfaction and adoption across organizations operating at scale. G2’s findings show a 4.5 out of 5-star rating from more than 500 verified reviews, with 91% of users indicating they would recommend the platform. Customers gave high marks for key capabilities, including Role-Based Permissions, Deal Management, and Content Repository, with Ease of Doing Business With
Fortegra Appoints Mark Rattner as President4.6.2026 15:00:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra" or the "Company"), a global specialty insurer and part of DB Insurance Co., Ltd., today announced the appointment of Mark Rattner as President. Mr. Rattner, who previously served as Executive Vice President and Chief Underwriting Officer, Insurance, brings a decade of Fortegra leadership and long-standing relationships with reliable distribution partners to his expanded role. Drawing on disciplined underwriting expertise built over a career spanning more than three decades, Mr. Rattner is focused on delivering the highest value and consistent results to the agents and brokers the company serves. His appointment reflects Fortegra’s continued investment in the people and partnerships that drive long-term, sustainable profitability. “Mark has been central to building Fortegra into the company it is today. His industry experience, knowledge, and trade craft make him the right person for this role. As we continue to evolve, Mark will enhance our partners
Tsuno Rice Fine Chemicals: Comparative Absorption Study of Rice Bran-Derived “Rice Magnesium” Reveals New Insights into Its Gradual, Sustained Absorption Profile4.6.2026 15:00:00 CEST | Press release
Tsuno Rice Fine Chemicals Co., Ltd. announced findings from an in-house human study showing that its proprietary rice bran-derived ingredient, “Rice Magnesium,” delivers gradual, sustained magnesium absorption compared with other magnesium sources. The results suggest potential benefits for sleep maintenance, muscle fatigue management during prolonged exercise, and gentler digestive tolerance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604576648/en/ Tsuno Rice Fine Chemicals: Differences in Absorption Among Magnesium Supplements Product Name: Rice Magnesium Most magnesium ingredients currently available on the market are mineral-derived. In contrast, Rice Magnesium is a rare plant-based magnesium ingredient sourced from rice bran, developed through Tsuno’s long-standing rice bran research. Composition: Magnesium phosphate Source Material: Japanese rice bran Study Background Magnesium is an essential mineral involved i
CSC Adds .BRAND Advisory and Domain Security Services to CrowdStrike Marketplace through Expanded Partnership4.6.2026 15:00:00 CEST | Press release
Expanded offering provides critical domain management and security support CSC, the world's leading enterprise-class domain registrar and online brand protection provider, today announced that its .BRAND services are now available on the CrowdStrike Marketplace. Building on CSC’s existing integration with the CrowdStrike Falcon® platform, this new listing provides enterprises with advanced domain advisory and security support to help them navigate the ICANN New gTLD Program application window, open now until August 12, 2026. As artificial intelligence (AI) drives increased activity across digital assets and domain name system (DNS) infrastructure, managing domain portfolios is a key part of enterprise cybersecurity. With CSC’s .BRAND services available on the CrowdStrike Marketplace, customers can centralize control and reduce reliance on third-party domains. By establishing a DNS trust anchor with centralized authentication aligned to zero-trust principles, organizations that use .BRA
New Study Reveals the True Environmental Impact of Periodontal Disease – And What You Can Do About It4.6.2026 14:33:00 CEST | Press release
Peer reviewed life cycle assessment published in the Journal of Dentistry (ISO 14040/14044-compliant) finds most impact comes from clinical care pathways, making prevention at home the biggest lever to improving outcomes for patients and the environment. Today P&G Oral Care announces the release of a new, first-of-its kind LCA study published in the Journal of Dentistry finds managing advanced periodontal disease can be associated with up to ~10× higher environmental impact compared with maintaining periodontal health through at-home prevention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601115251/en/ Oral-B iO9 Black The peer-reviewed paper, titled “Quantifying the Environmental Impact Potential from Periodontal Health to Disease: Findings from a Life Cycle Assessment Study,” for the first time quantifies the environmental burden associated with the presence of periodontal disease, its progression and the associated
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom